Pediatric Drug Labeling: Improving the Safety and Efficacy of Pediatric Therapies

JAMA

Volumn 290, Issue 7, 2003, Pages 905-911

  Roberts, Rosemary ^a   Rodriguez, William ^a   Murphy, Dianne ^a   Crescenzi, Terrie ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALPHA2B INTERFERON; AMMONIUM LACTATE; ANTIFUNGAL AGENT; ANTIMALARIAL AGENT; ANTIVIRUS AGENT; ANXIOLYTIC AGENT; ATOVAQUONE PLUS PROGUANIL; AZELASTINE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAMETHASONE; BETAMETHASONE DIPROPIONATE; BRIMONIDINE; BUSPIRONE; CALCITRIOL; CLOTRIMAZOLE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DIDANOSINE; ENALAPRIL MALEATE; ETODOLAC; FENTANYL DERIVATIVE; FLUVOXAMINE MALEATE; GABAPENTIN; HYPNOTIC SEDATIVE AGENT; IBUPROFEN; IMMUNOMODULATING AGENT; INSULIN GLARGINE; KETOROLAC TROMETAMOL; LAMIVUDINE; LORATADINE; METFORMIN; MEVINOLIN; MIDAZOLAM; OXAPROZIN; PEMIROLAST; PIMECROLIMUS; PROPOFOL; RANITIDINE; REBETRON; RIBAVIRIN; SEROTONIN UPTAKE INHIBITOR; SEVOFLURANE; SOTALOL; STAVUDINE; UNINDEXED DRUG;

AGITATION; ARTICLE; BRADYCARDIA; CARDIOVASCULAR DISEASE; CHILD; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG INDICATION; DRUG INFORMATION; DRUG LABELING; DRUG MARKETING; DRUG SAFETY; FLUSHING; FOOD AND DRUG ADMINISTRATION; HOSTILITY; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; HYPOPITUITARISM; INTENSIVE CARE UNIT; LICENSING; LONG QT SYNDROME; NERVOUSNESS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; PULMONARY HYPERTENSION; RESPIRATORY DISTRESS; RESPIRATORY TRACT INFECTION; SEIZURE; SIDE EFFECT; SUICIDAL BEHAVIOR; TREMOR; VOMITING; ADOLESCENT; DRUG THERAPY; EVALUATION; INFANT; LEGAL ASPECT; MARKETING; NEWBORN; PEDIATRICS; PRESCHOOL CHILD; SAFETY; STANDARD; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DRUG LABELING; DRUG THERAPY; HUMANS; INFANT; INFANT, NEWBORN; MARKETING; PEDIATRICS; SAFETY; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0042195862     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.290.7.905     Document Type: Article

References (21)

1. Shirkey H. Editorial comment: therapeutic orphans. J Pediatr. 1968;72:119-120.
2. Cote C, Kaufmann R, Troendle G, Lambert H. Is the "therapeutic orphan" about to be adopted? Pediatrics. 1996;98:118-123.
3. US Food and Drug Administration. Pediatric Exclusivity Provision: Status Report to Congress. Rockville, Md: Food and Drug Administration; 2001.
4. 't Jong WT, Vulto A, DeHoog M, Schimmel KJ, Tibboel D, Van den Anker JN. Unapproved and off label use of drugs in a children's hospital. N Engl J Med. 2000;343:1125.
5. Rodriguez W, Roberts R, Murphy D. Adverse drug events in children: the US Food and Drug Administration perspective. Curr Ther Res. 2001;62:711-723.
6. Committee on Drugs. Unapproved uses of approved drugs: the physician, the package insert, and the Food and Drug Administration: subject review. Pediatrics. 1996;98:143-145.
7. Gravilov V, Lifskitz M, Levy J, Gorodischer R. Unlicensed and "off label" medication use in a general pediatrics ambulatory hospital unit in Israel. Isr Med Assoc J. 2000;2:595-597.
8. Avenel S, Bomkratz A, Dassieu G, Janaud JC, Danan C. The incidence of prescriptions without marketing product license in a neonatal intensive care unit. Arch Pediatr. 2000;7:143-147.
9. Labeling and prescription drug advertising: content and format for labeling for human prescription drugs, 44 Federal Register 37434 (1979).
10. Specific requirements on content and format of labeling for human prescription drugs: revision of "pediatric use" subsection in the labeling, 59 Federal Register 64240 (1994).
11. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients, 63 Federal Register 66631 (1998).
12. Best Pharmaceuticals for Children Act. Pub L No. 107-109.
13. US Food and Drug Administration. Guidance for Industry: Qualifying for Pediatric Exclusivity Under Section 505A of the Federal Food, Drug and Cosmetic Act. Rockville, Md: Food and Drug Administration; 1999.
14. Physicians' Desk Reference. 54th ed. Montvale, NJ: Medical Economics Co Inc; 2000.
15. Siberry GK, Iannani R, eds. Harriett Lane Handbook. 15th ed. St Louis, Mo: Mosby Inc; 2000.
16. McIntyre J, Conroy S, Avery A, Corns H, Choonara I. Unlicensed and "off label" prescribing of drugs in general practice. Arch Dis Child. 2000;83:498-501.
17. Conroy S, McIntyre J, Choonara I. Unlicensed and "off label" drug use in neonates. Arch Dis Child Fetal Neonatal Ed. 1999;80:F142-F145.
18. Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and "off label" drug use in pediatric wards in European countries. BMJ. 2000;320:79-82.
19. International Conference on Harmonisation: guidance on E11 clinical investigation of medicinal products in the pediatric population, 65 Federal Register 78493 (2000).
20. Conroy S, McIntyre J, Choonara I. Unlicensed and off label use in neonates [reply letter]. Arch Dis Child Fetal Neonatal Ed. 2000;82:F77.
21. Steinbrook R. Testing medications in children. N Engl J Med. 2002;347:1462-1470.